IP Library Granted Patent US 8,778,335
Granted Patent B2
US 8,778,335 · App. 12/046,252 · Granted Jul 15, 2014

Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders

Inventor: Joan M. Fallon (Yonkers, NY)
Assignee: Curemark, LLC
A61K38/54A61K2300/00G01N33/52A23V2200/322A23V2200/32C12N9/94G01N30/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,778,335
App. No.
12/046,252
Granted
Jul 15, 2014
Kind
B2
Abstract

A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.

Claims (12)

1. A method of treating an individual having Parkinson's disease with a therapeutically effective amount of a pharmaceutical composition comprising a protease, a lipase, and an amylase, comprising:

measuring a level of fecal chymotrypsin in a stool sample of the individual;

comparing the level of fecal chymotrypsin with a normal fecal chymotrypsin level; and

administering the pharmaceutical composition comprising a protease, a lipase, and an amylase to the individual if the level of fecal chymotrypsin in the individual is less than the normal fecal chymotrypsin level.

2. The method of claim 1 , wherein the pharmaceutical composition is administered to the individual in an amount effective to promote protein digestion in the individual.

3. The method of claim 1 , wherein the normal fecal chymotrypsin level is approximately 8.4 U/gram.

4. A method of treating an individual having Parkinson's disease comprising:

administering a pharmaceutical composition comprising a protease, a lipase, and an amylase to the individual if the level of fecal chymotrypsin in the individual is less than a normal fecal chymotrypsin level, wherein the level of fecal chymotrypsin is measured in a stool sample of the individual.

5. The method of claim 4 , wherein the normal fecal chymotrypsin level is approximately 8.4 U/gram.

6. The method of claim 1 or 4 , wherein the pharmaceutical composition is an oral dosage form suitable for human use.

7. The method of claim 1 or 4 , wherein one or more symptoms of Parkinson's disease is ameliorated in the individual.

8. The method of claim 4 , wherein the individual having Parkinson's disease has one or more symptoms selected from the group consisting of: constipation, bowel movement frequency, tremors, falls, and difficulty in ambulation, and a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2009
From: FALLON, JOAN M.
To: CUREMARK, LLC
Reel/Frame 022626/0948 →
Continuity (5)
Division 11555697 · Nov 2, 2006
Continuation In Part 10730567 · Dec 8, 2003
Continuation 09929592 · Aug 14, 2001
Provisional Application 60224991 · Aug 14, 2000
Related Publication 20080152637A1 · Jun 26, 2008